SAN FRANCISCO, July 18, 2017 /PRNewswire/ -- Audentes
Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company
focused on developing and commercializing gene therapy products for
patients living with serious, life-threatening rare diseases, today
announced the appointment of Fulvio
Mavilio, Ph.D. to Vice President Scientific Affairs,
Europe. Dr. Mavilio will be based in Paris.
"We are extremely pleased to add Fulvio to the Audentes team,"
stated Matthew R. Patterson,
President and Chief Executive Officer. "He is an
internationally recognized scientific leader who has made important
contributions to the fields of molecular genetics and gene therapy
for rare diseases. He will be a significant resource as we continue
to advance our pipeline of programs, highlighted in the near term
by the planned initiation of international Phase 1/2 clinical
trials of AT132 to treat X-Linked Myotubular Myopathy and AT342 to
treat Crigler-Najjar Syndrome."
Prior to joining Audentes, Dr. Mavilio served as Scientific
Director of Genethon, Evry, France
(2012-2017). Prior to that he was co-Director of the Center for
Regenerative Medicine of the University of Modena, Italy
(2006-2011), Director of Discovery of Molmed SpA (2002-2005),
founder and Chief Scientific Officer of Genera SpA (1999-2002), and
co-Director of the San Raffaele-Telethon Institute of Gene Therapy
in Milan, Italy (1995-2002). Dr.
Mavilio is a member of the European Molecular Biology Association
(EMBO), Member of the Board of the American Society of Gene and
Cell Therapy (ASGCT), and a member of the Editorial Board of many
international journals in the fields of genetics, molecular biology
and gene therapy. He graduated in Biology at the University of
Rome in 1976, obtained a Ph.D. in
Medical Genetics at the School of Medicine of the same University
in 1979, and trained as a visiting scientist at the Wistar
Institute in Philadelphia, PA from
1985 to 1989. An expert and a pioneer in the fields of gene therapy
and stem cell research, Dr. Mavilio has published over 170 articles
in major international journals. He also serves as Professor of
Molecular Biology at the University of Modena and Reggio Emilia (Modena, Italy).
"I am thrilled to be joining Audentes at such an exciting time
and look forward to continuing to develop the company's European
efforts in particular," stated Dr. Mavilio, Ph.D. "With its
multi-product pipeline, established large-scale cGMP manufacturing
capability, and world-class team, Audentes has established itself
as a leading gene therapy company and is well-positioned for future
success."
About Audentes Therapeutics, Inc.
Audentes
Therapeutics (Nasdaq: BOLD) is a biotechnology company focused on
developing and commercializing gene therapy products for patients
living with serious, life-threatening rare diseases. We have
four product candidates in development, AT132 for the treatment of
X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of
Crigler-Najjar Syndrome, AT982 for the treatment of Pompe disease,
and AT307 for the treatment of the CASQ2 subtype of
Catecholaminergic Polymorphic Ventricular Tachycardia
(CASQ2-CPVT). We are a focused, experienced and passionate
team committed to forging strong, global relationships with the
patient, research and medical communities.
For more information regarding Audentes, please visit
www.audentestx.com.
Forward Looking Statements
This press release contains forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995, including, but not limited to, the
company's 2017 development and manufacturing plans and the expected
benefits of the company's product candidates. All statements
other than statements of historical fact are statements that could
be deemed forward-looking statements. Although the company
believes that the expectations reflected in such forward-looking
statements are reasonable, the company cannot guarantee future
events, results, actions, levels of activity, performance or
achievements, and the timing and results of biotechnology
development and potential regulatory approval is inherently
uncertain. Forward-looking statements are subject to risks and
uncertainties that may cause the company's actual activities or
results to differ significantly from those expressed in any
forward-looking statement, including risks and uncertainties
related to the company's ability to advance its product candidates,
obtain regulatory approval of and ultimately commercial its product
candidates, the timing and results of preclinical and clinical
trials, the company's ability to fund development activities and
achieve development goals, the company's ability to protect
intellectual property and other risks and uncertainties
described under the heading "Risk Factors" in documents the company
files from time to time with the Securities and Exchange
Commission. These forward-looking statements speak only as of the
date of this press release, and the company undertakes no
obligation to revise or update any forward-looking statements to
reflect events or circumstances after the date hereof.
Audentes Contacts
Investor Contact:
Thomas Soloway, CFO
415.818.1040
ir@audentestx.com
Media Contact:
Paul Laland
415.519.6610
media@audentestx.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/audentes-therapeutics-announces-appointment-of-fulvio-mavilio-phd-to-vice-president-scientific-affairs-europe-300489693.html
SOURCE Audentes Therapeutics, Inc.